Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain.

Strøm TB, Holla ØL, Tveten K, Cameron J, Berge KE, Leren TP.

Mol Genet Metab. 2010 Sep;101(1):76-80. doi: 10.1016/j.ymgme.2010.05.003.

PMID:
20659812
2.

A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.

Holla ØL, Strøm TB, Cameron J, Berge KE, Leren TP.

Mol Genet Metab. 2010 Feb;99(2):149-56. doi: 10.1016/j.ymgme.2009.09.012.

PMID:
19828345
3.

Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.

Tveten K, Holla ØL, Cameron J, Strøm TB, Berge KE, Laerdahl JK, Leren TP.

Hum Mol Genet. 2012 Mar 15;21(6):1402-9. doi: 10.1093/hmg/ddr578.

4.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.

PLoS One. 2013 May 13;8(5):e64145. doi: 10.1371/journal.pone.0064145.

5.

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.

Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, Seidah NG.

Traffic. 2007 Jun;8(6):718-32. Erratum in: Traffic. 2007 Jul;8(7):950.

6.
7.

Sorting an LDL receptor with bound PCSK9 to intracellular degradation.

Leren TP.

Atherosclerosis. 2014 Nov;237(1):76-81. doi: 10.1016/j.atherosclerosis.2014.08.038. Review.

PMID:
25222343
8.

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.

Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13045-50. doi: 10.1073/pnas.0806312105.

9.

Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.

Gu HM, Adijiang A, Mah M, Zhang DW.

J Lipid Res. 2013 Dec;54(12):3345-57. doi: 10.1194/jlr.M041129.

10.

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.

Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH.

J Biol Chem. 2007 Jun 22;282(25):18602-12.

PMID:
17452316
11.

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.

Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carfí A.

EMBO Rep. 2011 Dec 1;12(12):1300-5. doi: 10.1038/embor.2011.205.

12.

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.

Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG.

J Biol Chem. 2008 Jan 25;283(4):2363-72.

PMID:
18039658
13.

Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.

Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, Tarachandani A, De Francesco R, Wright SD, Sparrow CP, Carfi A, Sitlani A.

J Biol Chem. 2007 Jul 13;282(28):20502-12.

PMID:
17493938
14.

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA.

Biochem Biophys Res Commun. 2008 Oct 10;375(1):69-73. doi: 10.1016/j.bbrc.2008.07.106.

PMID:
18675252
15.

Molecular basis for LDL receptor recognition by PCSK9.

Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1820-5. doi: 10.1073/pnas.0712064105.

16.

Binding to the low-density lipoprotein receptor accelerates futile catalytic cycling in PCSK9 and raises the equilibrium level of intramolecular acylenzyme.

Geoghegan KF, Hoth LR, Varghese AH, Lin W, Boyd JG, Griffor MC.

Biochemistry. 2009 Apr 7;48(13):2941-9. doi: 10.1021/bi802232m.

PMID:
19222187
17.

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.

Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley MJ, Ruggeri L, Cummings RT, Cubbon RM, Santoro JC, Ehrhardt A, Lewis D, Fisher TS, Ha S, Njimoluh L, Wood DD, Hammond HA, Wisniewski D, Volpari C, Noto A, Lo Surdo P, Hubbard B, Carfí A, Sitlani A.

J Biol Chem. 2010 Apr 23;285(17):12882-91. doi: 10.1074/jbc.M110.113035.

18.

β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.

Starr AE, Lemieux V, Noad J, Moore JI, Dewpura T, Raymond A, Chrétien M, Figeys D, Mayne J.

FEBS J. 2015 Jul;282(14):2682-96. doi: 10.1111/febs.13309.

19.
20.

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

Maxwell KN, Fisher EA, Breslow JL.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2069-74.

Items per page

Supplemental Content

Support Center